急性病毒性肝炎患者血脂、血糖、蛋白、尿酸变化特点及其与预后的关联

doi:10.3877/cma.j.issn.2095-2015.2024.05.003

目的

分析急性病毒性肝炎患者血脂、血糖、蛋白、尿酸变化特点及其与预后的关联。

方法

纳入徐州医科大学附属徐州市立医院2020年1月至2023年1月收治的100例急性病毒性肝炎患者为试验组，选取同期60例健康体检者为对照组，比较试验组与对照组入院时血脂、血糖、蛋白、尿酸、凝血酶原活动度（PTA）差异。试验组治疗8周后，根据预后，将其分为预后良好组、预后不良组，比较2组患者上述指标差异，总结上述指标与患者肝功能及预后的关联。

结果

试验组谷丙转氨酶（ALT）、谷草转氨酶（AST）和总胆红素（TBIL）；甘油三酯（TG）、空腹血糖（FPG）；总蛋白（TP）、尿酸均高于对照组，总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、前白蛋白（PA）、白蛋白（ALB）均低于对照组（P<0.05）。治疗后试验组100例患者中，71例达到治愈标准，21例预后不良。预后良好组ALT、AST、TBIL和TG、FPG、TP、尿酸均低于对照组，TC、HDL-C、LDL-C、ALB、PA、PTA高于对照组（P<0.05）。

结论

部分急性病毒性肝炎患者预后不理想，与入院时血脂、血糖、蛋白、尿酸水平显著异常有关，且上述指标异常的加剧往往伴随着肝功能显著损伤。

关键词: 急性病毒性肝炎, 血脂, 尿酸, 预后

Objective

To analyze the changes of blood lipid, blood glucose, protein and uric acid in patients with acute viral hepatitis and their correlation with prognosis.

Methods

A total of 100 patients with acute viral hepatitis admitted to the Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University from January 2020 to January 2023 were included in the experimental group, and 60 healthy people in the same period were selected and included in the control group. The differences of blood lipid, blood glucose, protein, uric acid and prothrombin activity (PTA) between the experimental group and the control group were compared. According to the prognosis of the experimental group after 8 weeks of treatment, the patients were divided into good prognosis group and poor prognosis group respectively. The differences of the above indexes between the two groups were compared, and the correlation between the above indexes and the liver function and prognosis of the patients was summarized.

Results

Alanine aminotransferase (ALT), glutamic oxaloacetic transaminase (AST), total bilirubin (TBIL), triglyceride (TG), fasting blood-glucose (FPG), total protein (TP) and uric acid in the experimental group were higher than those in the control group, while total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), prealbumin (PA) and albumin (ALB) were lower than those in the control group (P<0.05). Among 100 patients in the experimental group, 71 cases reached the cure standard, and 21 cases had poor prognosis. ALT, AST, TBIL, TG, FPG, TP and uric acid in the good prognosis group were lower than those in the control group, while TC, HDL-C, LDL-C, ALB, PA and PTA were higher than those in the control group (P<0.05).

Conclusion

The prognosis of some patients with acute viral hepatitis is not ideal, which is related to the remarkable abnormality of blood lipid, blood glucose, protein and uric acid at admission, and the aggravation of the above indexes is often accompanied by the remarkable damage of liver function.

Key words: Acute viral hepatitis, Blood lipids, Uric acid, Prognosis

表1 2组临床资料比较

组别	例数	年龄(岁,±s)	体重指数(kg/m²,±s)	性别[例(%)]		文化水平[例(%)]
组别	例数	年龄(岁,±s)	体重指数(kg/m²,±s)	男	女	高中及以下	高中以上
试验组	100	61.33±7.59	23.50±1.38	55(55.00)	45(45.00)	61(61.00)	39(39.00)
对照组	60	61.26±7.84	23.41±1.26	34(56.67)	23(38.33)	36(60.00)	24(40.00)
t/χ²值		0.056	0.412	0.042		0.016
P值		0.956	0.681	0.837		0.900

表1 2组临床资料比较

组别	例数	年龄(岁,±s)	体重指数(kg/m²,±s)	性别[例(%)]		文化水平[例(%)]
组别	例数	年龄(岁,±s)	体重指数(kg/m²,±s)	男	女	高中及以下	高中以上
试验组	100	61.33±7.59	23.50±1.38	55(55.00)	45(45.00)	61(61.00)	39(39.00)
对照组	60	61.26±7.84	23.41±1.26	34(56.67)	23(38.33)	36(60.00)	24(40.00)
t/χ²值		0.056	0.412	0.042		0.016
P值		0.956	0.681	0.837		0.900

表2 2组肝功能、血脂、蛋白等实验室指标比较（

±s）

组别	例数	ALT(U/L)	AST(U/L)	TBIL(μmol/L)	TC(mmol/L)	TG(mmol/L)	HDL-C(mmol/L)	LDL-C(mmol/L)
试验组	100	1266.83±157.96	482.89±31.57	95.66±16.99	3.61±0.57	2.28±0.26	0.65±0.11	1.96±0.35
对照组	60	17.95±2.38	19.24±2.19	12.31±1.64	4.74±0.88	1.05±0.13	1.33±0.23	2.53±0.49
t值		61.160	113.454	37.847	9.858	34.143	25.186	8.556
P值		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
组别	例数	FPG(mmol/L)	TP(g/L)	PA(g/L)	ALB(g/L)	尿酸(μmol/L)	PTA(%)
试验组	100	9.55±0.16	73.59±6.08	211.54±11.39	38.16±1.99	326.27±14.26	65.26±6.69
对照组	60	5.13±0.74	68.61±5.71	259.88±12.53	40.41±2.48	252.59±11.58	85.33±11.73
t值		57.638	5.130	25.026	6.303	33.867	10.478
P值		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

表2 2组肝功能、血脂、蛋白等实验室指标比较（

±s）

组别	例数	ALT(U/L)	AST(U/L)	TBIL(μmol/L)	TC(mmol/L)	TG(mmol/L)	HDL-C(mmol/L)	LDL-C(mmol/L)
试验组	100	1266.83±157.96	482.89±31.57	95.66±16.99	3.61±0.57	2.28±0.26	0.65±0.11	1.96±0.35
对照组	60	17.95±2.38	19.24±2.19	12.31±1.64	4.74±0.88	1.05±0.13	1.33±0.23	2.53±0.49
t值		61.160	113.454	37.847	9.858	34.143	25.186	8.556
P值		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
组别	例数	FPG(mmol/L)	TP(g/L)	PA(g/L)	ALB(g/L)	尿酸(μmol/L)	PTA(%)
试验组	100	9.55±0.16	73.59±6.08	211.54±11.39	38.16±1.99	326.27±14.26	65.26±6.69
对照组	60	5.13±0.74	68.61±5.71	259.88±12.53	40.41±2.48	252.59±11.58	85.33±11.73
t值		57.638	5.130	25.026	6.303	33.867	10.478
P值		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

表3 预后良好组与预后不良组入院时肝功能、血脂、蛋白等实验室指标比较（

±s）

组别	例数	ALT(U/L)	AST(U/L)	TC(mmol/L)	TG(mmol/L)	HDL-C(mmol/L)	LDL-C(mmol/L)	TP(g/L)
预后良好组	71	1266.83±124.38	482.89±22.49	3.98±0.36	1.76±0.19	0.85±0.06	2.14±0.39	71.99±3.54
预后不良组	29	1531.51±139.61	602.81±26.53	2.70±0.29	3.55±0.20	0.16±0.03	1.52±0.31	77.51±4.18
t值		9.316	22.946	17.009	42.104	58.870	7.626	6.708
P值		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
组别	例数	PA(g/L)	ALB(g/L)	尿酸(μmol/L)	PTA(%)	FPG(mmol/L)	TBIL(μmol/L)
预后良好组	71	226.83±9.26	39.05±5.97	301.38±11.75	72.19±8.25	8.54±0.11	95.66±11.48
预后不良组	29	174.11±8.71	35.98±8.81	387.21±13.69	48.29±7.03	12.02±0.29	143.21±13.69
t值		26.270	2.018	31.573	13.692	87.362	17.755
P值		<0.001	0.046	<0.001	<0.001	<0.001	<0.001

表3 预后良好组与预后不良组入院时肝功能、血脂、蛋白等实验室指标比较（

±s）

组别	例数	ALT(U/L)	AST(U/L)	TC(mmol/L)	TG(mmol/L)	HDL-C(mmol/L)	LDL-C(mmol/L)	TP(g/L)
预后良好组	71	1266.83±124.38	482.89±22.49	3.98±0.36	1.76±0.19	0.85±0.06	2.14±0.39	71.99±3.54
预后不良组	29	1531.51±139.61	602.81±26.53	2.70±0.29	3.55±0.20	0.16±0.03	1.52±0.31	77.51±4.18
t值		9.316	22.946	17.009	42.104	58.870	7.626	6.708
P值		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
组别	例数	PA(g/L)	ALB(g/L)	尿酸(μmol/L)	PTA(%)	FPG(mmol/L)	TBIL(μmol/L)
预后良好组	71	226.83±9.26	39.05±5.97	301.38±11.75	72.19±8.25	8.54±0.11	95.66±11.48
预后不良组	29	174.11±8.71	35.98±8.81	387.21±13.69	48.29±7.03	12.02±0.29	143.21±13.69
t值		26.270	2.018	31.573	13.692	87.362	17.755
P值		<0.001	0.046	<0.001	<0.001	<0.001	<0.001

[1]	方芳, 李爽, 刁玲玲, 等. 病毒性肝炎患者肝活体组织检查后心理危机状况及相关因素[J]. 中国医药导报, 2022, 19(29): 81-84.
[2]	Tu C M, Wei T E, Tseng G S, et al. Serum uric acid is associated with incident metabolic syndrome independent of body shape index and body roundness index in healthy individuals[J]. Nutr Metab Cardiovasc Dis, 2021, 31(11): 3142-3151.
[3]	Wang M, Chen W Y, Zhang J, et al. Elevated fructose and uric acid through aldose reductase contribute to experimental and human alcoholic liver disease[J]. Hepatology, 2020, 72(5): 1617-1637.
[4]	王立蓉, 俞谦, 孟桂霞, 等. 老年病毒性肝炎病人继发肝硬化危险因素分析[J]. 实用老年医学, 2020, 34(6): 558-561.
[5]	Lin S, Zhang T, Zhu L, et al. Characteristic dysbiosis in gout and the impact of a uric acid-lowering treatment, febuxostat on the gut microbiota[J]. J Genet Genomics, 2021, 48(9): 781-791.
[6]	王川雨, 陈奕君, 林尤直. 影响索非布韦联合雷迪帕韦治疗丙型病毒性肝炎疗效的因素及其预测价值研究[J]. 中国临床药理学杂志, 2020, 36(7): 741-743, 759.
[7]	盛秋菊, 韩超, 丁洋, 等. 慢性乙型肝炎抗病毒治疗与疾病长期预后——慢性乙型肝炎防治指南(2019年版)更新要点解读[J]. 中国实用内科杂志, 2020, 40(6): 441-445.
[8]	Qu J, Dou J, Wang A, et al. Fatty liver index for hyperuricemia diagnosis: a community-based cohort study[J]. BMC Endocrine Disorders, 2022, 22(1): 1-9.
[9]	Borghi C, Domienik-Karłowicz J, Tykarski A, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update[J]. Cardiol J, 2021, 28(1): 1-14.
[10]	杨小兵, 邹娇娇, 陈邦华, 等. 2004-2017年武汉市病毒性肝炎流行病学特征分析[J]. 中国预防医学杂志, 2019, 20(1): 42-47.
[11]	Katsiki N, Dimitriadis GD, Mikhailidis DP. Serum uric acid and diabetes: from pathophysiology to cardiovascular disease[J]. Current Pharmaceutical Design, 2021, 27(16): 1941-1951.
[12]	杨甲, 饶慧瑛. 中国丙型病毒性肝炎流行趋势及治疗获益[J]. 临床药物治疗杂志, 2021, 19(12): 6-11.
[13]	Zhang Y, Pan R, Xu Y, et al. Treatment of refractory gout with TNF-α antagonist etanercept combined with febuxostat[J]. Ann Palliat Med, 2020, 9(6): 4332-4338.
[14]	虞接军, 刘中夫, 李健. 慢性丙型病毒性肝炎患者健康相关生命质量的研究进展[J]. 中国艾滋病性病, 2023, 29(2): 230-233.
[15]	Chao G, Chen L. Study on the independent effect of thyroid hormone based on uric acid level on NAFLD[J]. J Heal Popul Nutr, 2021, 40(1): 1-7.
[16]	薛红, 姚敏, 岳明, 等. 303例丙型病毒性肝炎患者的生化特征分析[J]. 东南国防医药, 2019, 21(5): 455-459.
[17]	刘沁雨, 常越, 张青, 等. 血清尿酸对非酒精性脂肪性肝病进展期肝纤维化/肝硬化的诊断价值[J/OL]. 中华肝脏病杂志(电子版), 2020,12(1):24-30.
[18]	Zeng H, Tang C, Lin B, et al. The regulation effect of GLUT9/SLC2A9 on intrahepatic uric acid level and metabolic associated fatty liver disease[J]. Hepatol Int, 2022, 16(5): 1064-1074.
[19]	Feng Y, Zheng S, Liu L, et al. Association of serum uric acid with hepatic steatosis detected by controlled attenuation parameter in the United States population[J]. Lipids Health Dis, 2023, 22(1): 1-8.
[20]	Wang J, Abdus S, Tan C, et al. Serum uric acid level negatively correlated with the prevalence of clopidogrel low response in patients undergoing antiplatelet treatment with aspirin and clopidogrel[J]. Nutr Metabol Cardiovasc Dis, 2020, 30(12): 2215-2220.
[21]	Zhang X, Cui J, Hou J, et al. Research Progress of Natural Active Substances with Uric-Acid-Reducing Activity[J]. J Agric Food Chem, 2022, 70(50): 15647-15664.
[22]	Peng L, Wu S, Zhou N, et al. Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity[J]. BMC Pediatrics, 2021, 21(1): 1-8.
[23]	Khan JUA, Fayaz H, Wahab A, et al. Association Between Serum Uric Acid and Nonalcoholic Fatty Liver Disease: A Case Control Study[J]. Pak J Med Heal Sci, 2023, 17(2): 662-662.
[24]	Jang TY, Huang CI, Yeh ML, et al. Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents[J]. J Gastroenterol Hepatol, 2020, 35(3): 473-481.
[25]	Zhou Y, Li W, Huang Y. A low serum uric acid concentration predicts a poor prognosis in adult patients with candidemia[J]. Open Med, 2022, 17(1): 1077-1083.

[1]	张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2]	许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3]	高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4]	李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5]	梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[6]	张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[7]	李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[8]	陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[9]	韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[10]	董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[11]	刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[12]	陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[13]	曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[14]	沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[15]	王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Changes of blood lipid, blood glucose, protein and uric acid in patients with acute viral hepatitis and their correlation with prognosis

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Changes of blood lipid, blood glucose, protein and uric acid in patients with acute viral hepatitis and their correlation with prognosis